argenxARGX
ARGX
About: Argenx is a Dutch company focused on using its antibody engineering technology to treat rare autoimmune diseases. Vyvgart (efgartigimod) was initially approved in the US in December 2021 as a treatment for generalized myasthenia gravis, followed by approvals in Europe and Japan in 2022.
Employees: 1,148
0
Funds holding %
of 6,809 funds
0
Analysts bullish %
of 14 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
54% more first-time investments, than exits
New positions opened: 54 | Existing positions closed: 35
25% more capital invested
Capital invested by funds: $15.1B [Q2] → $19B (+$3.83B) [Q3]
16% more repeat investments, than reductions
Existing positions increased: 133 | Existing positions reduced: 115
6% more funds holding
Funds holding: 331 [Q2] → 350 (+19) [Q3]
6% more call options, than puts
Call options by funds: $292M | Put options by funds: $275M
0% more funds holding in top 10
Funds holding in top 10: 20 [Q2] → 20 (+0) [Q3]
0.68% less ownership
Funds ownership: 59.26% [Q2] → 58.58% (-0.68%) [Q3]
Research analyst outlook
14 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$605
3%
downside
Avg. target
$660
6%
upside
High target
$723
16%
upside
14 analyst ratings
13 positive
93%
1 neutral
7%
0 negative
0%
Wells Fargo Derek Archila 53% 1-year accuracy 19 / 36 met price target | 16%upside $723 | Overweight Maintained | 19 Dec 2024 |
Oppenheimer Leland Gershell 53% 1-year accuracy 29 / 55 met price target | 8%upside $675 | Outperform Reiterated | 21 Nov 2024 |
Evercore ISI Group Gavin Clark-Gartner 40% 1-year accuracy 4 / 10 met price target | 13%upside $706 | Outperform Maintained | 21 Nov 2024 |
HC Wainwright & Co. Douglas Tsao 43% 1-year accuracy 71 / 167 met price target | 1%downside $617 | Buy Reiterated | 20 Nov 2024 |
Wolfe Research Andy Chen 56% 1-year accuracy 9 / 16 met price target | 12%upside $697 | Outperform Upgraded | 12 Nov 2024 |
Financial journalist opinion
Neutral
GlobeNewsWire
3 weeks ago
argenx to Present at Upcoming Investor Conferences
November 26, 2024 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that members of the management team will participate in the following upcoming investor conferences in December.
Neutral
GlobeNewsWire
1 month ago
argenx Advances Clinical Development of Efgartigimod SC in Idiopathic Inflammatory Myopathies
Phase 2 data establish proof-of-concept of efgartigimod SC in myositis Enrollment to continue in Phase 3 across all three subtypes (IMNM, ASyS, DM) under evaluation in ALKIVIA Potential for efgartigimod SC to be first targeted approach for myositis patients who have limited treatment options November 20, 2024, 7:00 AM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced the decision to continue development of efgartigimod subcutaneous (SC) (efgartigimod alfa and hyaluronidase-qvfc) in the ongoing Phase 2/3 ALKIVIA study in adults with idiopathic inflammatory myopathies (IIM or myositis), following analysis of topline data from the Phase 2 portion of the study. ALKIVIA will continue to enroll patients across each of the three myositis subtypes in the study, including immune-mediated necrotizing myopathy (IMNM), anti-synthetase syndrome (ASyS), and dermatomyositis (DM).
Neutral
Business Wire
1 month ago
Steritas Announces Collaboration with argenx to Advance Evidence for Novel Steroid-sparing Therapeutics
BOSTON--(BUSINESS WIRE)--Steritas LLC., a company dedicated to enhancing care for steroid-treated patients, today announced a licensing agreement with argenx, a global immunology company, for use of its STOX® Suite of steroid-toxicity clinical outcome assessments (COAs) across argenx's development programs for differentiated immunology therapeutics. The STOX Suite comprises first-in-class digital instruments that provide a standardized and validated measure of the full scope of steroid-toxicity.
Neutral
Business Wire
1 month ago
Zai Lab and argenx Announce Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in China
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) and argenx (Euronext & Nasdaq: ARGX) today announced that China's National Medical Products Administration (NMPA) approved the supplemental Biologics License Application (sBLA) for VYVGART Hytrulo 1,000mg (5.6ml)/vial [Efgartigimod Alfa Injection (Subcutaneous Injection)] for the treatment of adult patients with chronic inflammatory demyelinating polyneuropathy (CIDP). VYVGART Hytrulo is approved for CI.
Neutral
GlobeNewsWire
1 month ago
argenx and Zai Lab Announce Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy in China
First and only NMPA-approved treatment for patients with CIDP in China Second VYVGART Hytrulo indication approved in China November 11, 2024 – 7:30am ET Amsterdam, the Netherlands— argenx SE (Euronext & Nasdaq: ARGX) and Zai Lab Limited (Nasdaq: ZLAB; HKEX: 9688) today announced that China's National Medical Products Administration (NMPA) approved the supplemental Biologics License Application (sBLA) for VYVGART Hytrulo 1,000mg (5.6ml)/vial [efgartigimod alfa injection (subcutaneous injection)] for the treatment of adult patients with chronic inflammatory demyelinating polyneuropathy (CIDP). VYVGART Hytrulo is approved for CIDP as a once weekly 30-to-90 second subcutaneous injection.
Positive
Zacks Investment Research
1 month ago
Why Argenx (ARGX) Might be Well Poised for a Surge
Argenx (ARGX) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Positive
Zacks Investment Research
1 month ago
Is Argenx (ARGX) Outperforming Other Medical Stocks This Year?
Here is how argenex SE (ARGX) and Novartis (NVS) have performed compared to their sector so far this year.
Neutral
GlobeNewsWire
1 month ago
argenx to Participate at Upcoming Investor Conferences
November 5, 2024 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that members of the management team will participate in the following upcoming investor conferences in November:
Positive
Seeking Alpha
1 month ago
Argenx: Strong CIDP Launch, But gMG Growth Propels Q3 Sales Beat
argenx reported strong Q3 results with the sales outperformance being primarily driven by the gMG uptake of Vyvgart. Initial contribution from the CIDP launch also exceeded expectations. The growth outlook for 2025 has further improved after the Q3 results.
Neutral
Seeking Alpha
1 month ago
argenx SE (ARGX) Q3 2024 Earnings Call Transcript
argenx SE (NASDAQ:ARGX ) Q3 2024 Earnings Conference Call October 31, 2024 8:30 AM ET Company Participants Beth DelGiacco – Vice President, Corporate Communications and Investor Relations Tim Van Hauwermeiren – Chief Executive Officer Karl Gubitz – Chief Financial Officer Karen Massey – Chief Operating Officer Conference Call Participants Derek Archila – Wells Fargo Tazeen Ahmad – Bank of America James Gordon – JPMorgan Allison Bratzel – Piper Sandler Myles Minter – William Blair Alex Thompson – Stifel Danielle Brill – Raymond James Amy Li – Jefferies Yaron Werber – TD Cowen Vikram Purohit – Morgan Stanley Charles Pitman-King – Barclays Samantha Semenkow – Citi Gavin Clark-Gartner – Evercore ISI Suzanne van Voorthuizen – Kempen Joel Beatty – Baird Joon Lee – Truist Securities Victor Floc'h – BNP Paribas Xian Deng – UBS Leland Gershell – Oppenheimer Andy Chen – Wolfe Research Rajan Sharma – Goldman Sachs Thomas Smith – Leerink Partners Douglas Tsao – H. C. Wainwright David Seynnaeve – Petercam Emmanuel Papadakis – Deutsche Bank Simon Baker – Redburn Atlantic Operator Good morning.
Charts implemented using Lightweight Charts™